NEW YORK, Oct. 26, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD).


Previous articleDelix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board
Next articlePT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of New Psychedelics